Biocryst Pharma Inc (BCRX) Stock Price, Quote & News

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 919 859 1302

Fax: 919 859 1314

Website: www.biocryst.com

Address:

4505 Emperor Boulevard, Suite 200, Durham, United States

Jumpmanz Mar. 15 at 8:57 PM

$BCRX let’s ride!

0 · Reply

clownmarket Mar. 15 at 8:27 PM

$BCRX One consequence of the European sale is that pretty much all of my charts are now useless. Although I was tracking US orladeyo revenue separately, there is no expenses breakdown pre-2024 So I've created a new chart from the non-GAAP numbers given to us in last earnings, they highlight cashflow which is the most important metric of them all. Operating cashflow and leveraged FCF My leveraged FCF number is taken from the true FCF and then I add back the European business cash expenses. ALL revenue numbers in the two new charts exclude Euro revenue For 2026 I've put in the guidance midpoint, giving operating cashflow of 188m. These numbers include Astria P3 expenses. You can see you don't need much extra revenue to beat 2025 cashflow *despite the new P3 trial expenses* The LAST chart in this group is the true top and bottom line numbers, including everything, and as you can see it's useless now for judging anything

0 · Reply

Paulzk Mar. 15 at 2:59 PM

$BCRX Khamenei, had misgivings about his son replacing him, multiple sources familiar with the matter told CBS News. The analysis showed the elder Khamenei was wary of his son, Ayatollah Mojtaba Khamenei, ever taking power because he was perceived as not very bright, and was viewed as unqualified to be leader, according to sources. https://www.cbsnews.com/news/us-intelligence-iran-supreme-leader-mojtaba-khamenei-father-sources-say/

1 · Reply

drose0527 Mar. 14 at 9:34 PM

$KOS next week play book for Kos price action Monday- look for continuation of Gap up run as chart has shown it rhythm and should test 2.55-2.65 level. Putting us right underneath sell off candle. Tuesday- look for push higher to test prior resistance candle. Could be a green or red day but I’ll error on red day finishing on lower end of candle Wednesday& Thursday- look for chop action very tight candles small retrace by end of Thursday session. Sitting roughly at 2.48-2.52 level Friday will be price pinned to 2.50 options expiration. Most likely trying to make options not print and closing flat at a 2.49 price point thus giving market acceptance for higher valuations to move forward the following week. $IOVA $AQST $BCRX $AUR

1 · Reply

Merlintrader Mar. 14 at 7:56 PM

$BCRX https://www.merlintrader.com/biotech-trading-without-the-fairy-tales-risks-catalysts-and-reality/

1 · Reply

Paulzk Mar. 14 at 9:24 AM

$BCRX Trump Administration Readies Plans to Dismantle Renowned Science Lab Proposals include transferring a supercomputer to the University of Wyoming and shifting a space weather lab to a private company. https://www.nytimes.com/2026/03/13/climate/ncar-breakup-plan-nasa-noaa.html

0 · Reply

Paulzk Mar. 14 at 9:22 AM

$BCRX Meta (META.O), opens new tab is planning sweeping layoffs that could affect 20% or more of the company, three sources familiar with the matter told Reuters, as ‌Meta seeks to offset costly artificial intelligence infrastructure bets and prepare for greater efficiency brought about by AI-assisted workers. https://www.reuters.com/business/world-at-work/meta-planning-sweeping-layoffs-ai-costs-mount-2026-03-14/

0 · Reply

Theobviouschoice Mar. 13 at 10:30 PM

$BCRX talking about $8.4M

0 · Reply

Ttubular Mar. 13 at 9:31 PM

$BCRX AH volume over 1mill

1 · Reply

drose0527 Mar. 13 at 9:16 PM

$BCRX 15 minute chart on the close of the day! Look at the 2 biggest candles at end of day the last 30 minutes had roughly 800k in volume and a bullish engulfing candle! Could be signs of Monday being our turning point we shall see. But those 2 candles represent almost 20% of total volume traded! I. Today’s 5 million. Let’s see what Monday brings????

1 · Reply

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 26, 2026, 3:08 PM EST - 17 days ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 7:00 AM EST - 17 days ago

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Feb 17, 2026, 7:00 AM EST - 26 days ago

BioCryst to Present at Upcoming Investor Conference

Feb 11, 2026, 7:00 AM EST - 4 weeks ago

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 5, 2026, 7:01 AM EST - 5 weeks ago

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

Jan 23, 2026, 9:00 AM EST - 7 weeks ago

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Jan 12, 2026, 3:56 PM EST - 2 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 2 months ago

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

Jan 6, 2026, 7:00 AM EST - 2 months ago

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 12, 2025, 7:06 AM EST - 3 months ago

FDA expands approval of BioCryst's rare disease drug for use in young children

Dec 12, 2025, 7:00 AM EST - 3 months ago

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

Dec 3, 2025, 7:00 AM EST - 3 months ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Nov 24, 2025, 2:23 PM EST - 3 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 6, 2025, 8:00 AM EST - 4 months ago

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Nov 3, 2025, 12:16 PM EST - 4 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 7:00 AM EST - 4 months ago

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 7:00 AM EDT - 5 months ago

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 20, 2025, 7:00 AM EDT - 5 months ago

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Oct 17, 2025, 3:20 PM EDT - 5 months ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

ATXS

Oct 14, 2025, 1:16 PM EDT - 5 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript

Oct 14, 2025, 12:20 PM EDT - 5 months ago

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

ATXS

Oct 14, 2025, 7:35 AM EDT - 5 months ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS

Oct 14, 2025, 7:00 AM EDT - 5 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

ATXS

Oct 1, 2025, 7:00 AM EDT - 5 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Sep 29, 2025, 2:53 AM EDT - 5 months ago

BioCryst: Blue Light Special In Small Cap Biotech Aisle

Sep 5, 2025, 5:47 AM EDT - 6 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Aug 11, 2025, 7:00 AM EDT - 7 months ago

BioCryst Announces Departure of Dr. Helen Thackray

Aug 4, 2025, 11:38 AM EDT - 7 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 7:00 AM EDT - 7 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 8 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 21, 2025, 7:00 AM EDT - 8 months ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 9, 2025, 7:00 AM EDT - 8 months ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 7, 2025, 7:00 AM EDT - 8 months ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jun 27, 2025, 7:00 AM EDT - 9 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 16, 2025, 7:00 AM EDT - 9 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 13, 2025, 7:00 AM EDT - 9 months ago

ORLADEYO® (berotralstat) Approved in Colombia

Jun 6, 2025, 7:00 AM EDT - 10 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 2, 2025, 7:00 AM EDT - 10 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

May 30, 2025, 7:00 AM EDT - 10 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 27, 2025, 7:00 AM EDT - 10 months ago

BioCryst to Present at Upcoming Investor Conferences

May 16, 2025, 7:00 AM EDT - 10 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 14, 2025, 7:00 AM EDT - 10 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 5, 2025, 5:29 PM EDT - 11 months ago

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

May 5, 2025, 2:05 PM EDT - 11 months ago

BioCryst: Strong Opportunity For A Double With A Proven Therapy

May 5, 2025, 12:54 PM EDT - 11 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 7:00 AM EDT - 11 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 11 months ago

BioCryst Appoints Steve Frank to Board of Directors

Apr 21, 2025, 7:00 AM EDT - 11 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

Jumpmanz Mar. 15 at 8:57 PM

$BCRX let’s ride!

0 · Reply

clownmarket Mar. 15 at 8:27 PM

0 · Reply

Paulzk Mar. 15 at 2:59 PM

1 · Reply

drose0527 Mar. 14 at 9:34 PM

1 · Reply

Merlintrader Mar. 14 at 7:56 PM

$BCRX https://www.merlintrader.com/biotech-trading-without-the-fairy-tales-risks-catalysts-and-reality/

1 · Reply

Paulzk Mar. 14 at 9:24 AM

0 · Reply

Paulzk Mar. 14 at 9:22 AM

0 · Reply

Theobviouschoice Mar. 13 at 10:30 PM

$BCRX talking about $8.4M

0 · Reply

Ttubular Mar. 13 at 9:31 PM

$BCRX AH volume over 1mill

1 · Reply

drose0527 Mar. 13 at 9:16 PM

1 · Reply

Ttubular Mar. 13 at 8:15 PM

$BCRX

1 · Reply

Ttubular Mar. 13 at 8:07 PM

$BCRX look at the last candle green candle before the close volume was 1.5 mill

1 · Reply

Fergus20 Mar. 13 at 7:37 PM

$BCRX ass piss

1 · Reply

Saffier1988 Mar. 13 at 7:31 PM

$BCRX daylow close

1 · Reply

Saffier1988 Mar. 13 at 7:05 PM

$BCRX shitshow! daylow close back to 7,50

1 · Reply

Fergus20 Mar. 13 at 4:23 PM

$BCRX dog shit

2 · Reply

drose0527 Mar. 13 at 3:42 PM

$BCRX things that make you go hmmm! We crossed the 60 day 3 weeks ago and the last 4 days over took the 180 that should be a golden cross! Rsi is at 60. Respecting the bull flag formation at cup edge at the 7 month chart inside larger cup on yearly! Macd is high but not out of contol. Where is the volume?????? That is the spark to ignite this powder keg? Hmmmm?

2 · Reply

TrustButVerifi Mar. 13 at 2:33 PM

$VKTX head up to my old friends ! $AUPH $BCRX

0 · Reply

drose0527 Mar. 13 at 2:05 PM

$BCRX 18,000shares on last print!

1 · Reply

drose0527 Mar. 13 at 2:04 PM

$BCRX it’s is so tight of a trade right now! Damn excited! This is literally like a rocket waiting to ignite! Damn! If today trades in 8.45-8.47 range all day money Monday is going to be a blast!

0 · Reply

drose0527 Mar. 13 at 1:53 PM

$BCRX we need volume!! Let’s pump up the volume! Need 10-12 million for launch this is ready to move! Waiting for tutes to jump in and lead the charge! Very bullish here! Gonna be a fun ride! $AQST $IOVA $KOS $AUR

1 · Reply

drose0527 Mar. 13 at 1:17 PM

$KOS looking for a 3 gap up day! With possible continuation into Monday before any pause! Next stop 2.75-2.85-3.00! $IOVA $AQST $AUR $BCRX

1 · Reply

Market Cap	2.06B
Revenue (ttm)	874.84M
Net Income (ttm)	263.86M
EPS (ttm)	N/A
PE Ratio	6.18
Forward PE	30.44
Profit Margin	30.16%
Debt to Equity Ratio	-4.02

Volume	5,516,600
Avg Vol	4,733,396
Day's Range	N/A - N/A
Shares Out	250.80M
Stochastic %K	9%
Beta	0.74
Analysts	Strong Sell
Price Target	$20.18